IN2015DN01328A - - Google Patents

Info

Publication number
IN2015DN01328A
IN2015DN01328A IN1328DEN2015A IN2015DN01328A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A IN 1328DEN2015 A IN1328DEN2015 A IN 1328DEN2015A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A
Authority
IN
India
Prior art keywords
compounds
present
therapeutic
cancer
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Patrick Dillon
Mika Lindvall
Daniel Poon
Savithri Ramurthy
Vivek Rauniyar
Cynthia Shafer
Sharadha Subramanian
Huw Tanner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN01328A publication Critical patent/IN2015DN01328A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN1328DEN2015 2012-09-19 2013-09-17 IN2015DN01328A (show.php)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2015DN01328A true IN2015DN01328A (show.php) 2015-07-03

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1328DEN2015 IN2015DN01328A (show.php) 2012-09-19 2013-09-17

Country Status (13)

Country Link
US (1) US9546173B2 (show.php)
EP (1) EP2897961B1 (show.php)
JP (1) JP6186440B2 (show.php)
KR (1) KR20150056550A (show.php)
CN (1) CN104640865B (show.php)
AU (1) AU2013318283A1 (show.php)
BR (1) BR112015005982A2 (show.php)
CA (1) CA2882410A1 (show.php)
EA (1) EA201590600A1 (show.php)
ES (1) ES2612885T3 (show.php)
IN (1) IN2015DN01328A (show.php)
MX (1) MX2015003535A (show.php)
WO (1) WO2014047020A1 (show.php)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882410A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
JP7349491B2 (ja) 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Il-17モジュレーターとしてのスピロ環状インダン類似体
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
AU2020319888A1 (en) * 2019-08-01 2022-02-24 Praetego, Inc. Inhibitors of advanced glycation end products
PL4073044T3 (pl) * 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe inhibitory BRAF jako związki przełamujące paradoks
PL4073065T3 (pl) 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe pochodne metylochinazolinonu
CN115443274B (zh) * 2020-04-30 2025-04-25 勤浩医药(苏州)有限公司 含苯基并内磺酰胺的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2007513172A (ja) * 2003-12-02 2007-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド 複素環式プロテインキナーゼインヒビターおよびその使用
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
BRPI0518509A2 (pt) 2005-01-10 2008-11-25 Pfizer pirrolopirazàis, inibidores de cinase potentes
HRP20110892T1 (hr) 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
BRPI0812450A2 (pt) 2007-06-05 2019-09-24 Schering Corp derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
JP2013542965A (ja) 2010-11-17 2013-11-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍の治療方法
BR112013021896A2 (pt) * 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
JP2015508785A (ja) 2012-03-02 2015-03-23 ジェネンテック, インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
CA2882410A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors

Also Published As

Publication number Publication date
EP2897961A1 (en) 2015-07-29
US9546173B2 (en) 2017-01-17
AU2013318283A1 (en) 2015-03-05
CA2882410A1 (en) 2014-03-27
WO2014047020A1 (en) 2014-03-27
EA201590600A1 (ru) 2015-07-30
MX2015003535A (es) 2015-07-14
CN104640865B (zh) 2018-05-11
CN104640865A (zh) 2015-05-20
JP6186440B2 (ja) 2017-08-23
EP2897961B1 (en) 2016-10-26
ES2612885T3 (es) 2017-05-19
BR112015005982A2 (pt) 2017-07-04
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
JP2015529248A (ja) 2015-10-05

Similar Documents

Publication Publication Date Title
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
TR201816379T4 (tr) DNA-PK inhibitörleri.
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
IN2014MN00986A (show.php)
GT201500051A (es) Inhibidores de glucosilceramida sintasa
GB201209613D0 (en) New compounds
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
PH12015501385A1 (en) Autotaxin inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN01328A (show.php)
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
GEP201606566B (en) Isoxazolidine derivatives